Cargando…

Response to the Letter to the Editor Regarding “Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials”

Detalles Bibliográficos
Autores principales:	Suez, Daniel, Stein, Mark, Gupta, Sudhir, Hussain, Iftikhar, Melamed, Isaac, Paris, Kenneth, Darter, Amy, Bourgeois, Christelle, Fritsch, Sandor, Leibl, Heinz, McCoy, Barbara, Gelmont, David, Yel, Leman
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2017
Materias:	Letter to Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5662656/ https://www.ncbi.nlm.nih.gov/pubmed/28875256 http://dx.doi.org/10.1007/s10875-017-0438-y

Ejemplares similares

Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America
por: Suez, Daniel, et al.
Publicado: (2016)

Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency
por: Wasserman, Richard L., et al.
Publicado: (2016)

Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials
por: Ballow, Mark, et al.
Publicado: (2017)

Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies
por: Borte, M., et al.
Publicado: (2016)

Correction to: Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials
por: Ballow, Mark, et al.
Publicado: (2018)

Patient experience with subcutaneous immunoglobulin 20%, Ig20Gly, for primary immunodeficiency diseases: a prespecified post hoc analysis of combined data from 2 pivotal trials
por: Meckley, Lisa M., et al.
Publicado: (2020)

Ten-year population trends of immunoglobulin use, burden of adult antibody deficiency and feasibility of subcutaneous immunoglobulin (SCIg) replacement in Hong Kong Chinese
por: Kan, Andy Ka Chun, et al.
Publicado: (2022)

Steady-State Serum IgG Trough Levels Are Adequate for Pharmacokinetic Assessment in Patients with Immunodeficiencies Receiving Subcutaneous Immune Globulin
por: Li, Zhaoyang, et al.
Publicado: (2021)

Effects of Body Mass and Age on the Pharmacokinetics of Subcutaneous or Hyaluronidase-facilitated Subcutaneous Immunoglobulin G in Primary Immunodeficiency Diseases
por: Li, Zhaoyang, et al.
Publicado: (2023)

A clinician’s guide for administration of high-concentration and facilitated subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency diseases
por: Epland, Kristin, et al.
Publicado: (2022)

Implications to payers of switch from hospital-based intravenous immunoglobulin (IVIg) to home-based subcutaneous immunoglobulin (SCIg) therapy in patients with primary immunodeficiencies (PID) and secondary immunodeficiencies (SID) in Canada
por: Gerth, William C, et al.
Publicado: (2014)

SCIg vs. IVIg: let’s give patients the choice!
por: Samaan, Kathryn K, et al.
Publicado: (2014)

Quality of Life Differences for Primary Immunodeficiency Patients on Home SCIG versus IVIG
por: Anterasian, Christine, et al.
Publicado: (2019)

Individualizing Therapy in CIDP: A Mini-Review Comparing the Pharmacokinetics of Ig With SCIg and IVIg
por: Beydoun, Said R., et al.
Publicado: (2021)

Demonstration of safety of intravenous immunoglobulin in geriatric patients in a long-term, placebo-controlled study of Alzheimer's disease
por: Gelmont, David, et al.
Publicado: (2016)

SCIG administration: A promising and patient convenient alternative for those receiving long-term IVIG
por: Hassini, Slim, et al.
Publicado: (2022)

New Frontiers in Subcutaneous Immunoglobulin Treatment
por: Jolles, Stephen, et al.
Publicado: (2011)

Pediatric subset of primary immunodeficiency patients treated with SCIG: post hoc analysis of SHIFT and IBIS pooled data
por: Moschese, Viviana, et al.
Publicado: (2020)

Real-World Evidence of Tolerability of 20% Subcutaneous Immunoglobulin Treatment
por: Rosenbach, Kevin, et al.
Publicado: (2023)

Selective IgA Deficiency
por: Yel, Leman
Publicado: (2010)

Safety, Efficacy and Pharmacokinetics of a New 10% Liquid Intravenous Immunoglobulin (IVIG) in Patients with Primary Immunodeficiency
por: Wasserman, Richard L., et al.
Publicado: (2012)

Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies
por: Kobayashi, Roger H., et al.
Publicado: (2019)

Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig(®)) in the treatment of patients with primary immunodeficiencies
por: Kobayashi, Roger H, et al.
Publicado: (2022)

Initiation of immunoglobulin therapy by subcutaneous administration in immunodeficiency patients naive to replacement therapy
por: Koterba, Alan P, et al.
Publicado: (2014)

Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig(®)]) in the treatment of patients with primary immunodeficiencies
por: Kobayashi, Roger H., et al.
Publicado: (2022)

Use of subcutaneous immunoglobulin in inflammatory myositis
por: Zhou, Alan L, et al.
Publicado: (2021)

Common variable immunodeficiency associated with microdeletion of chromosome 1q42.1-q42.3 and inositol 1,4,5-trisphosphate kinase B (ITPKB) deficiency
por: Louis, Ankmalika G, et al.
Publicado: (2016)

Medical journals and advertiser tracking—Consequences for patients, clinicians, and editors
por: Gupta, Ravi, et al.
Publicado: (2023)

Subcutaneous Immunoglobulin 16.5% (Cutaquig®) in Primary Immunodeficiency Disease: Safety, Tolerability, Efficacy, and Patient Experience with Enhanced Infusion Regimens
por: Gupta, Sudhir, et al.
Publicado: (2023)

Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency
por: Jolles, Stephen
Publicado: (2013)

Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients With Primary Immunodeficiency
por: Hagan, John B., et al.
Publicado: (2010)

Impact of IVIG vs. SCIG on IgG trough level and infection incidence in primary immunodeficiency diseases: A systematic review and meta-analysis of clinical studies()
por: Shrestha, Pragya, et al.
Publicado: (2019)

Subcutaneous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy
por: Goyal, Namita A., et al.
Publicado: (2021)

Pneumococcal Antibody Titers: A Comparison of Patients Receiving Intravenous Immunoglobulin Versus Subcutaneous Immunoglobulin
por: Abghari, Pamella F., et al.
Publicado: (2017)

Scleromyxedema with Subcutaneous Nodules: Successful Treatment with Thalidomide and Intravenous Immunoglobulin
por: Dolenc-Voljč, M., et al.
Publicado: (2013)

Long-term treatment of refractory myasthenia gravis with subcutaneous immunoglobulin
por: Kovács, Edina, et al.
Publicado: (2017)

Subcutaneous Immunoglobulins are a Valuable Treatment Option in Myasthenia Gravis
por: Garnero, Martina, et al.
Publicado: (2018)

Outcome Evaluation of a Subcutaneous Immunoglobulin Clinical Management Program
por: Zhu, Julia, et al.
Publicado: (2019)

Long-term treatment with subcutaneous immunoglobulin in multifocal motor neuropathy
por: Gentile, Luca, et al.
Publicado: (2021)

Use of subcutaneous immunoglobulin in stiff person syndrome: Case series
por: Aljarallah, Salman, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nvh4jfh10o3d6dr2s9ae52r083